In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 4, 2015, Pages 259-263

  Pfaller, M A ^a,b   Rhomberg, P R ^b   Messer, S A ^b   Castanheira, M ^b  

^a UNIVERSITY OF IOWA   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

Antifungal susceptibility; Candida; Echinocandins

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; HISTONE DEACETYLASE INHIBITOR; MGCD 290; MICAFUNGIN; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ENZYME INHIBITOR;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA KUDRIAVZEVII; PRIORITY JOURNAL; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; ECHINOCANDINS; ENZYME INHIBITORS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84925041893     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.11.008     Document Type: Article

References (41)

1. Alexander B.D., Johnson M.D., Pfeiffer C.D., Jimenez-Ortigosa C., Catania J., Booker R., Castanheira M., Messer S.A., Perlin D.S., Pfaller M.A. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013, 56:1724-1732.
2. Arendrup M.C., Dzajic E., Jensen R.H., Johansen H.K., Kjaeldgaard P., Knudsen J.D., Kristensen L., Leitz C., Lemming L.E., Nielsen L., Olesen B., Rosenvinge F.S., Roder B.L., Schonheyder H.C. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin Microbiol Infect 2013, 19:E343-E353.
3. Castanheira M., Woosley L.N., Pfaller M.A., Diekema D.J., Messer S.A., Jones R.N. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob Agents Chemother 2010, 54:2655-2659.
4. Castanheira M., Woosley L.N., Messer S.A., Diekema D.J., Jones R.N., Pfaller M.A. Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. Antimicrob Agents Chemother 2014, 58:577-580.
5. Chaturvedi V., Ramani R., Ghannoum M.A., Killian S.B., Holliday N., Knapp C., Ostrosky-Zeichner L., Messer S.A., Pfaller M.A., Iqbal N.J., Arthington-Skaggs B.A., Vazquez J.A., Sein T., Rex J.H., Walsh T.J. Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother 2008, 52:1500-1502.
6. Clinical and Laboratory Standards Institute (CLSI) M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts 2008, CLSI, Wayne, PA. 3rd ed.
7. Clinical and Laboratory Standards Institute (CLSI) M27-S4. Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement 2012, CLSI, Wayne, PA.
8. Cowen L.E., Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 2005, 309:2185-2189.
9. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 2004, 54:854-869.
10. Dannaoui E., Desnos-Ollivier M., Garcia-Hermoso D., Grenouillet F., Cassaing S., Baixench M.T., Bretagne S., Dromer F., Lortholary O. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012, 18:86-90.
11. Garcia-Effron G., Lee S., Park S., Cleary J.D., Perlin D.S. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 2009, 53:3690-3699.
12. Garcia-Effron G., Chua D.J., Tomada J.R., DiPersio J., Perlin D.S., Ghannoum M., Bonilla H. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob Agents Chemother 2010, 54:2225-2227.
13. Grozinger C.M., Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002, 9:3-16.
14. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389:349-352.
15. Healey K.R., Katiyar S.K., Raj S., Edlind T.D. CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction. Mol Microbiol 2012, 86:303-313.
16. Heitman J. Cell biology. A fungal Achilles' heel. Science 2005, 309:2175-2176.
17. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 2004, 48:693-715.
18. Kim J.H., Mahoney N., Chan K.L., Molyneux R.J., May G.S., Campbell B.C. Chemosensitization of fungal pathogens to antimicrobial agents using benzo analogs. FEMS Microbiol Lett 2008, 281:64-72.
19. Lepak A., Castanheira M., Diekema D., Pfaller M., Andes D. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob Agents Chemother 2012, 56:5875-5882.
20. Li Y., Sun S., Guo Q., Ma L., Shi C., Su L., Li H. In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 2008, 61:577-585.
21. Mai A., Rotili D., Massa S., Brosch G., Simonetti G., Passariello C., Palamara A.T. Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg Med Chem Lett 2007, 17:1221-1225.
22. Matthews R.C., Rigg G., Hodgetts S., Carter T., Chapman C., Gregory C., Illidge C., Burnie J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003, 47:2208-2216.
23. McElhaney-Feser G.E., Raulli R.E., Cihlar R.L. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother 1998, 42:2342-2346.
24. Moody J.A. Synergism testing. Broth microdilution, checkerboard, and broth macrodilution methods. Clinical Microbiology Procedures Hndbook 1991, vol. 1:5.18.1-5.18.28. American Society for Microbiology, Washington, DC.
25. Moradei O., Maroun C.R., Paquin I., Vaisburg A. Histone deacetylase inhibitors: latest developments, trends and prospects. Curr Med Chem Anticancer Agents 2005, 5:529-560.
26. Ostrosky-Zeichner L. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida. Clin Infect Dis 2013, 56:1733-1734.
27. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
28. Perlin D.S. Echinocandin-resistant Candida: Molecular methods and phenotypes. Curr Fungal Infect Rep 2011, 5:113-119.
29. Pfaller M.A., Diekema D.J. Azole antifungal drug cross-resistance: mechanisms epidemiology, and clinical significance. J Invasive Fungal Infect 2007, 1:74-92.
30. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 2012, 50:2846-2856.
31. Pfaller M.A., Messer S.A., Georgopapadakou N., Martell L.A., Besterman J.M., Diekema D.J. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009, 47:3797-3804.
32. Pfaller M.A., Castanheira M., Lockhart S.R., Ahlquist A.M., Messer S.A., Jones R.N. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012, 50:1199-1203.
33. Pfaller M.A., Messer S.A., Woosley L.N., Jones R.N., Castanheira M. Echinocandin and triazole antifungal susceptibility profiles of opportunistic yeast and mould clinical isolates (2010-2011); application of new CLSI clinical breakpoints and epidemiological cutoff values to characterize geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013, 51:2571-2581.
34. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., Alexander B.D. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010, 48:2373-2380.
35. Robbins N., Leach M.D., Cowen L.E. Lysine deacetylases Hda1 and Rpd3 regulate Hsp90 function thereby governing fungal drug resistance. Cell Rep 2012, 2:878-888.
36. Sanglard D., Odds F.C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2:73-85.
37. Shields R.K., Nguyen M.H., Press E.G., Updike C.A., Clancy C.J. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob Agents Chemother 2013, 57:3528-3535.
38. Singh S.D., Robbins N., Zaas A.K., Schell W.A., Perfect J.R., Cowen L.E. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog 2009, 5:e1000532.
39. Slater J.L., Howard S.J., Sharp A., Goodwin J., Gregson L.M., Alastruey-Izquierdo A., Arendrup M.C., Warn P.A., Perlin D.S., Hope W.W. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011, 55:3075-3083.
40. Smith W.L., Edlind T.D. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002, 46:3532-3539.
41. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000, 64:435-459.